<DOC>
	<DOCNO>NCT02430428</DOCNO>
	<brief_summary>The objective clinical trial evaluate safety effectiveness Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure reduction elimination myopia ≥ -1.00 D ≤ -10.00 D ≤ -3.00 D cylinder ( myopia without astigmatism ) MRSE ≤ -11.50 D .</brief_summary>
	<brief_title>Correction Myopia Wtih Without Astigmatism Using VisuMax™ Femtosecond Laser</brief_title>
	<detailed_description>This prospective multi-center clinical trial maximum 360 eye 360 consecutive subject enrol treat VisuMax™ Femtosecond Laser . The study conduct 8 clinical site . Subjects screen eligibility , informed consent obtain meet screen criterion interested participate study . Eligible subject examine preoperatively obtain medical history establish baseline ocular condition . Baseline postoperative measurement include manifest refraction , cycloplegic refraction , distance visual acuity ( best correct uncorrected ) , slit-lamp examination , fundus examination , corneal topography , central corneal pachymetry , mesopic pupil measurement , wavefront analysis , mesopic contrast sensitivity , intraocular pressure ( IOP ) . Only eyes astigmatism ≥ -0.75 D ≤ -3.00 D target full distance manifest spherocylindrical refraction , eye ( ) astigmatism &lt; -0.75 D target full distance manifest sphere-only refraction , enrol study . Subjects must astigmatism ≤ -3.00 D eye treat . Eyes astigmatism ≥ -0.75 D ≤ -3.00 D receive spherocylindrical treatment . Eyes astigmatism &lt; -0.75 D receive sphere-only treatment . Operative eye astigmatism ≥ -0.75 D ≤ -3.00 D must target full distance manifest spherocylindrical refraction . Operative eye ( ) astigmatism &lt; -0.75 D must target full distance manifest sphere-only refraction . Monovision treatment retreatments study eye allow course study . Bilateral investigational treatment allow study . Safety effectiveness criterion American National Standard Ophthalmics ( ANSI Z80.11-2012 ) - Laser Systems Corneal Reshaping utilized evaluation VisuMax Femtosecond Laser .</detailed_description>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Astigmatism</mesh_term>
	<criteria>1 . Male female subject age 22 year age old ; 2 . Myopia ≥ 1.00 D ≤ 10.00 D ≤ 3.00 D cylinder MRSE ≤ 11.50 D eye treat ; 3 . A stable refraction past year , demonstrate change MRSE ≤ 0.50 D eye treat ; 4 . A difference cycloplegic manifest refraction &lt; 0.75 D spherical equivalent eye treat ; 5 . UCVA worse 20/40 eye treat ; 6 . BSCVA least 20/20 eye treat ; 7 . Discontinue use contact lenses least 2 week ( hard lens ) 3 day ( soft lens ) prior preoperative examination , day surgery ; 8 . All contact lens wearer must demonstrate stable refraction ( within ±0.5 D ) , determine MRSE , two consecutive examination least 1 week apart , eye treat ; 9 . Central corneal thickness least 500 micron eye treat ; 10 . Willing able return schedule followup examination ; 11 . Able provide write informed consent follow study instruction English 1 . Mesopic pupil diameter &gt; 8.0 mm ; 2 . Cylinder &gt; 3.00 D ; 3 . Treatment depth le 250 micron corneal endothelium ; 4 . Eye treat targeted monovision ; 5 . Fellow eye BSCVA worse 20/40 ; 6 . Keratometry read via SimK value less 40.00 D ; 7 . Abnormal corneal topographic finding , e.g . keratoconus , pellucid marginal degeneration either eye ; 8 . History current anterior segment pathology , include cataract eye treat ; 9 . Clinically significant dry eye syndrome unresolved treatment either eye ; 10 . Residual , recurrent , active ocular uncontrolled eyelid disease , corneal scar corneal abnormality recurrent corneal erosion severe basement membrane disease eye treat ; 11 . Ophthalmoscopic sign progressive unstable myopia keratoconus ( keratoconus suspect ) either eye ; 12 . Irregular unstable ( distorted/not clear ) corneal mire central keratometry image either eye ; 13 . History ocular herpes zoster herpes simplex keratitis ; 14 . Deep orbit , strong blink , anxiety , pterygium , find suggest difficulty achieve maintain suction ; 15 . Difficulty follow direction unable fixate ; 16 . Previous intraocular corneal surgery kind eye treat , include type surgery either refractive therapeutic purpose ; 17 . History steroidresponsive rise intraocular pressure , glaucoma , preoperative IOP &gt; 21 mmHg either eye ; 18 . History diabetes , diagnose autoimmune disease , connective tissue disease clinically significant atopic syndrome ; 19 . Immunocompromised require chronic systemic corticosteroid immunosuppresive therapy may affect wound healing ; 20 . History known sensitivity plan study medication ; 21 . Participating ophthalmic drug device clinical trial time clinical investigation ; 22 . Pregnant , lactating , childbearing potential practicing medically approve method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>